Browse > Article
http://dx.doi.org/10.4062/biomolther.2012.103

Pharmacokinetics of Uridine Following Ocular, Oral and Intravenous Administration in Rabbits  

Kim, Eunyoung (College of Pharmacy, Chung-Ang University)
Kang, Wonku (College of Pharmacy, Yeungnam University)
Publication Information
Biomolecules & Therapeutics / v.21, no.2, 2013 , pp. 170-172 More about this Journal
Abstract
The pyrimidine nucleoside uridine has recently been reported to have a protective effect on cultured human corneal epithelial cells, in an animal model of dry eye and in patients. In this study, we investigate the pharmacokinetic profile of uridine in rabbits, following topical ocular (8 mg/eye), oral (450 mg/kg) and intravenous (100 mg/kg) administration. Blood and urine samples were serially taken, and uridine was measured by high-performance liquid chromatography-tandem mass spectrometry. No symptoms were noted in the animals after uridine treatment. Uridine was not detected in either plasma or urine after topical ocular administration, indicating no systemic exposure to uridine with this treatment route. Following a single intravenous dose, the plasma concentration of uridine showed a bi-exponential decay, with a rapid decline over 10 min, followed by a slow decay with a terminal half-life of $0.36{\pm}0.05$ h. Clearance and volume of distribution were $1.8{\pm}0.6$ L/h/kg and $0.58{\pm}0.32$ L/kg, respectively. The area under the plasma concentration-time curves (AUC) was $59.7{\pm}18.2{\mu}g{\cdot}hr/ml$, and urinary excretion up to 12 hr was ~7.7% of the dose. Plasma uridine reached a peak of $25.8{\pm}4.1{\mu}g/ml$ at $2.3{\pm}0.8$ hr after oral administration. The AUC was $79.0{\pm}13.9{\mu}g{\cdot}hr/ml$, representing ~29.4% of absolute bioavailability. About 1% of the oral dose was excreted in the urine. These results should prove useful in the design of future clinical and nonclinical studies conducted with uridine.
Keywords
Uridine; Pharmacokinetics; Topical ocular; Bioavailability; Rabbit;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Peters, G. J., van Groeningen, C. J., Laurensse, E., Kraal, I., Leyva A., Lankelma, J. and Pinedo, H. M. (1987) Effect of pyrimidine nucleosides on body temperatures of man and rabbit in relation to pharmacokinetic data. Pharm. Res. 4, 113-119.   DOI
2 Al Safarjalani, O. N., Zhou, X. J., Naguib, F. N., Shi, J., Schinazi, R. F. and el Kouni, M. H. (2001) Enhancement of the bioavailability of oral uridine by coadministration of 5-(phenylthio)acyclouridine, a uridine phosphorylase inhibitor: implications for uridine rescue regimens in chemotherapy. Cancer Chemother. Pharmacol. 48, 389-397.   DOI   ScienceOn
3 Chang, K. C., Oh, J. Y., In, Y. S., Kim, M. K., Shin, K.C., Wee, W. R., Lee, J. H. and Park, M. (2009) Preliminary effects of oral uridine on the ocular surface in dry eye patients. J. Kor. Med. Sci. 24, 701-707.   DOI   ScienceOn
4 Kang, W. Quantitative determination of uridine in rabbit plasma and urine by liquid chromatography coupled to a tandem mass spectrometry. (2012) Biomed. Chromatogr. 26, 541-544.   DOI   ScienceOn
5 Klubes, P., Geffen, D. B. and Cysyk, R. L. (1986) Comparison of the bioavailability of uridine in mice after either oral or parenteral administration. Cancer Chemother. Pharmacol. 17, 236-240.
6 Oh, J. Y, In, Y. S., Kim, M. K., Ko, J. H., Lee, H. J., Chin, K. C., Lee, S. M., Wee, W. R., Lee, J. H. and Park, M. (2007) Protective effect of uridine on cornea in a rabbit dry eye model. Invest. Ophthalmol. Vis. Sci., 48, 1102-1109.   DOI   ScienceOn